| Date | Title | Description |
| 29.04.2024 | Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations | -Richard Pascoe appointed Chairman of the Board of Directors to spearhead the ongoing business development discussions
NEW YORK, April 29, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage ... |
| 29.11.2021 | iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products | iX Biopharma will receive an initial US$9 million upfront payment
Eligible for up to US$239 million in development and sales milestone payments
Double digit royalties on future product sales of any licensed product
SINGAPORE, Nov. 29, 2021 ... |
| 25.11.2021 | iX Biopharma Signs Exclusive License Agreement For Wafermine And Other Sublingual Ketamine Wafer Products | iX Biopharma will receive an initial US$9 million upfront payment
Eligible for up to US$239 million in development and sales milestone payments
Double digit royalties on future product sales of any licensed product
SINGAPORE, Nov. 25, 2021 ... |
| 24.11.2021 | Seelos Therapeutics : Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine - Form 8-K | Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma's Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine
- New SLS-003 Program Extends Seelos' Ketamine Franchise into Additional Indications Inclu... |
| 24.11.2021 | Seelos Therapeutics : Agreement Includes the Option of up to an Additional $30 Million of Funding Contingent on Achievement of Certain Milestones - Form 8-K | - Agreement Includes the Option of up to an Additional $30 Million of Funding Contingent on Achievement of Certain Milestones
NEW YORK, Nov 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutica... |
| 03.11.2021 | Psychedelics Offer Hope for Mental Disorders, Addiction | NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Global destigmatization, changing regulations and an upswing in research are speaking loudly to the opportunity for psychedelics to provide tangible improvements in medicine to address some of the most... |
| 03.11.2021 | Psychedelics Offer Hope for Mental Disorders, Addiction | NetworkNewsWire Editorial Coverage
NEW YORK, Nov. 3, 2021 /PRNewswire/ -- Global destigmatization, changing regulations and an upswing in research are speaking loudly to the opportunity for psychedelics to provide tangible improvements in m... |
| 02.09.2021 | Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors | |
| 01.09.2021 | Seelos Therapeutics Announces Senior Management Appointments | |
| 09.08.2021 | Seelos Therapeutics Announces Mid-Year 2021 Business and Clinical Update | |
| 14.07.2021 | Seelos Therapeutics to Participate in Two Investor Conferences in August | |
| 07.07.2021 | Seelos Therapeutics Announces Positive In Vivo Data Demonstrating Down-Regulation of SNCA mRNA and Protein Expression from a Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 for Parkinson's Diseas... | |
| 06.07.2021 | Seelos Therapeutics Doses First Patient in Part 2 of a Registrational Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder | |
| 28.06.2021 | Seelos Therapeutics Added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes | |
| 01.06.2021 | Seelos Therapeutics Announces its Inclusion in the First U.S. Listed Exchange Traded Fund (ETF) Focused on Psychedelics | |
| 27.05.2021 | Seelos Therapeutics Receives European Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS) | |
| 20.05.2021 | Seelos Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock | |
| 19.05.2021 | Seelos Therapeutics Announces Proposed Public Offering of Common Stock | |
| 17.05.2021 | Seelos Therapeutics Announces Positive Topline Data from the Open-Label Study of SLS-002 (Intranasal Racemic Ketamine), Demonstrating a Significant Treatment Effect and a Well Tolerated Safety Profile... | |
| 20.04.2021 | Seelos Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis (ALS) | |
| 06.04.2021 | Seelos Therapeutics Announces a Strategic Device Partnership with AptarGroup, Inc. | |
| 05.03.2021 | Seelos Therapeutics Announces Completion of Open-Label Patient Enrollment of Proof of Concept Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with M... | |
| 18.02.2021 | Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase a Significant Portion of Royalties for SLS-002 (Intranasal Racemic Ketamine Program) | |
| 01.02.2021 | Seelos Therapeutics to Participate in Canaccord Genuity's New Paradigms and Treatment Approaches in Mental Health Conference February 3-4 | |
| 29.01.2021 | Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Australia | |
| 28.01.2021 | Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares | |
| 27.01.2021 | Seelos Therapeutics Announces its Inclusion in the First Psychedelic Exchange Traded Fund (ETF) | |
| 26.01.2021 | Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock | |
| 25.01.2021 | Seelos Therapeutics Announces Proposed Public Offering of Common Stock | |
| 22.01.2021 | Seelos Therapeutics Receives a Notice of Allowance in Japan for SLS-005 (Trehalose) | |
| 15.01.2021 | Seelos Therapeutics Announces Dosing of the First Patients in a Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder | |
| 06.01.2021 | Seelos Therapeutics Announces Year End 2020 Business Update | |
| 05.01.2021 | Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | |
| 21.12.2020 | Seelos Therapeutics Announces Issuance of a Patent for Trehalose (SLS-005) in Israel
USA - English
USA - English | |
| 15.12.2020 | Seelos Therapeutics Announces the Selection of SLS-005 (Trehalose) for the HEALEY ALS Platform Trial for Amyotrophic Lateral Sclerosis Led by the Harvard Medical School | |
| 14.12.2020 | Seelos Therapeutics Raises $10 Million In Private Placement of Senior Secured Convertible Note | |
| 02.12.2020 | Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | |
| 19.11.2020 | Seelos Therapeutics Receives US Orphan Drug Designation for SLS-005 (Trehalose) in Amyotrophic Lateral Sclerosis | |
| 09.11.2020 | Seelos Therapeutics to Participate in the 3rd International Conference on Sanfilippo Syndrome and Related Diseases | |
| 26.10.2020 | Seelos Therapeutics Announces Issuance of Composition of Matter Patent for SLS-007 | |
| 23.09.2020 | Seelos Therapeutics Announces Sponsored Research Agreement with Duke University for Gene Therapy Studies of SLS-004 in Parkinson's Disease | |
| 10.09.2020 | Seelos Therapeutics Receives Notice of Allowance for an Additional US Patent for Trehalose (SLS-005) | |
